Skip to main content
. 2021 Aug 26;9(8):e003132. doi: 10.1136/jitc-2021-003132

Figure 7.

Figure 7

Neoantigen-targeted personalized SVMAV preparation and its antitumor effect verification. (A) Workflow of the neoantigen-targeted personalized SVMAV. (B) Prediction of three neoantigens by exome sequencing of Hepa 1–6 cells. (C) Schematic of the HLS@SVMAV preparation. (D) Treatment scheme in the orthotopic HCC mouse model. (E) Photograph of mouse livers from different groups (n=5). (F) Quantification of tumor area by pixel counting. (G) Representative multiplex fluorescent IHC staining images of orthotopic HCC tissues. CD8a, green; F4/80, magenta; CD86, yellow; PD-L1, red; DAPI, blue. white scale bar represents 20 µm. Dashed circles delimit the F4/80+CD86+ M1 macrophages. aPD-1, antiprogrammed cell death protein 1; COI, cellular orthotopic injection; HCC, hepatocellular carcinoma; IHC, immunohistochemistry; SVMAV, Self-assembling Vehicle-free Multi-component Antitumor nanoVaccine.